title: Piceatannol enhances cisplatin sensitivity in ovarian cancer via modulation of p53, X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial fission.
abstract: Resistance to cisplatin (CDDP) in ovarian cancer (OVCA) arises from the dysregulation of tumor suppressors and survival signals. During genotoxic challenge, these factors can be influenced by secondary agents that facilitate the induction of apoptosis. Piceatannol is a natural metabolite of the stilbene resveratrol found in grapes and is converted from its parent compound by the enzyme CYP1BA1 p450. It has been hypothesized to exert specific effects against various cellular targets; however, its ability to influence CDDP resistance in cancer cells has not been investigated to date. Here, we show that piceatannol is a potent enhancer of CDDP sensitivity in OVCA, and this effect is achieved through the modulation of several major determinants of chemoresistance. Piceatannol enhances p53-mediated expression of the pro-apoptotic protein NOXA, increases XIAP degradation via the ubiquitin-proteasome pathway, and enhances caspase-3 activation. This response is associated with an increase in Drp1-dependent mitochondrial fission, leading to more effective induction of apoptosis. In vivo studies using a mouse model of OVCA reveal that a number of these changes occur in association with a greater overall reduction in tumor weight when mice are treated with both piceatannol and CDDP, in comparison to treatment with either agent alone. Taken together, these findings demonstrate the potential application of piceatannol to enhance CDDP sensitivity in OVCA, and it acts on p53, XIAP, and mitochondrial fission.
authors.affiliation: World Class University Major in Biomodulation, Department of Agricultural Biotechnology, College of Agriculture and Life Sciences, Seoul National University, Seoul, Republic of Korea.
authors.forename: Lee
authors.initials: L
authors.lastname: Farrand
authors.forename: Sanguine
authors.initials: S
authors.lastname: Byun
authors.forename: Ji Young
authors.initials: JY
authors.lastname: Kim
authors.forename: Akechai
authors.initials: A
authors.lastname: Im-Aram
authors.forename: Jihoon
authors.initials: J
authors.lastname: Lee
authors.forename: Semi
authors.initials: S
authors.lastname: Lim
authors.forename: Ki Won
authors.initials: KW
authors.lastname: Lee
authors.forename: Jeong-Yong
authors.initials: JY
authors.lastname: Suh
authors.forename: Hyong Joo
authors.initials: HJ
authors.lastname: Lee
authors.forename: Benjamin K
authors.initials: BK
authors.lastname: Tsang
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D053148:Caspase 3 / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000627:therapeutic use*; D004195:Disease Models, Animal; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D034281:Dynamins / Q000378:metabolism; D005260:Female; D006801:Humans; D051379:Mice; D063154:Mitochondrial Dynamics / Q000187:drug effects; D008954:Models, Biological; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D059748:Proteolysis / Q000187:drug effects; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D013267:Stilbenes / Q000494:pharmacology / Q000627:therapeutic use*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*; D054875:Ubiquitination / Q000187:drug effects; D051636:X-Linked Inhibitor of Apoptosis Protein / Q000378:metabolism*
chemical_list: C498702:PMAIP1 protein, human; D019253:Proto-Oncogene Proteins c-bcl-2; D013267:Stilbenes; D016159:Tumor Suppressor Protein p53; D051636:X-Linked Inhibitor of Apoptosis Protein; C041525:3,3',4,5'-tetrahydroxystilbene; D053148:Caspase 3; D046988:Proteasome Endopeptidase Complex; D034281:Dynamins; D002945:Cisplatin
keywords: Chemoresistance; Cisplatin; Mitochondria; Ovarian Cancer; Piceatannol; XIAp; p53